In this edition, trichloroethylene may be 'invisible' cause of PD, ravulizumab reduces clinical deterioration in generalized myasthenia gravis and more. Read the full coverage here: Trichloroethylene may be 'invisible and highly preventable' cause of Parkinson's disease DEA petitioned to de-schedule dual orexin receptor antagonist insomnia medications Ravulizumab reduces clinical deterioration in patients with generalized myasthenia gravis FDA places partial clinical hold on initiation of new patients in evobrutinib study FDA advisory committees rule in favor of Rexulti for agitation associated with Alzheimer's References: Dorsey ER, et al. J Parkinsons Dis. 2023;doi:10.3233?JPD-225047. Mantegazza R, et al. Poster 148: Ravulizumab reduces clinical deteriorations in patients with generalized myasthenia gravis: Results from the CHAMPION MG study. Presented at: Muscular Dystrophy Association Clinical & Scientific Conference; March 19-22, 2023; Dallas. Press Release Press Release Press Release

Ver todos los episodios